Press Releases

Mimetogen pharmaceuticals completes enrollment of mim-728 phase 3 trial for tavilermide for dry eye disease 31 March 2020
Mimetogen Pharmaceuticals Enters Into Licensing Agreement with Allergan to Develop and Commercialize Tavilermide (MIM-D3) Topical Dry Eye Treatment 04 November 2015
Mimetogen Pharmaceuticals Announces Expiration of Exclusive Option Agreement with Bausch + Lomb 11 September 2014
Mimetogen Pharmaceuticals Announces Topline Results of Its Second Clinical Study with MIM-D3 for the Treatment of Dry Eye Syndrome 09 September 2014
Mimetogen Pharmaceuticals Inc. Expands Its Board of Directors 01 June 2009
Mimetogen Pharmaceuticals Inc. Announces Initiation of a Phase 3 Clinical Trial with MIM-D3 to Treat Dry Eye Syndrome 10 October 2013
Bausch + Lomb Acquires Option to License New Compound to Treat Dry Eye Syndrome (DES) 18 July 2013
Mimetogen Pharmaceuticals Completes Key Equity Financing for Ophthalmology Drugs 07 October 2009
Mimetogen Pharmaceuticals Inc. Announces Issuance of Key US Patent Protecting the Use of MIM-D3 to Treat Dry Eye Syndrome 28 November 2012
Mimetogen Pharmaceuticals Inc. Appoints Kim Brazzell, Ph.D. as Chief Medical Officer 05 January 2012
Mimetogen Pharmaceuticals Inc. Announces Positive Top Line Data from Phase II Clinical Trial of MIM-D3 for Dry Eye Syndrome 26 June 2011
Mimetogen Pharmaceuticals Announces Completion of Series B Financing and Enrollment of 100th Patient in Phase II Trial 25 February 2011
Mimetogen Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Novel NGF Mimetic in Patients with Dry Eye Syndrome 22 November 2010